tiprankstipranks
Advertisement
Advertisement
First Tracks Biotherapeutics price target raised to $65 from $45 at UBS
PremiumThe FlyFirst Tracks Biotherapeutics price target raised to $65 from $45 at UBS
10d ago
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
Premium
The Fly
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
24d ago
First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo
Premium
The Fly
First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo
24d ago
PremiumRatingsBuy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo
1M ago
First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo
Premium
The Fly
First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo
2M ago
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway
Premium
Ratings
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway
3M ago
First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyFirst Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright
4M ago
TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating
Premium
Ratings
TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating
4M ago
First Tracks Biotherapeutics initiated with an Outperform at Leerink
Premium
The Fly
First Tracks Biotherapeutics initiated with an Outperform at Leerink
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100